Evidence map›Paper›PMID 38529279›Full record

ArticleFrontiers in immunology2024

Identification of mouse CD4

Laura Bricio-Moreno, Juliana Barreto de Albuquerque, Jake M Neary, Thao Nguyen, Lucy F Kuhn, YeePui Yeung, Kathryn M Hastie, Sara Landeras-Bueno, Eduardo Olmedillas, Chitra Hariharan and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Laura Bricio-MorenoCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
Juliana Barreto de AlbuquerqueCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
Jake M NearyCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
Thao NguyenCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
Lucy F KuhnCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
YeePui YeungCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States.
Sara Landeras-BuenoCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States.
Eduardo OlmedillasCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States.
Chitra HariharanCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States.
Anusha NathanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Matthew A GetzRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Alton C GaytonRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Ashok KhatriHarvard Medical School, Boston, MA, United States.
Gaurav D GaihaHarvard Medical School, Boston, MA, United States.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States.
Andrew D LusterCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
James J MoonCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States.
Harvard University · USLa Jolla Institute for Immunology · USMassachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · USMGH Institute of Health Professions · US

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
Technology and Computational CoreP01AI165072 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LUSTER, ANDREW D · 2021 to 2023
$19.6M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV CureDP1DA058476 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$4.7M
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA RepliconsR01AI176533 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$3.5M
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7M
NIAID NIH HHS DP2 AI154421NIAID NIH HHS P01 AI165072NIAID NIH HHS R01 AI176533NIDA NIH HHS DP1 DA058476NIDDK NIH HHS P30 DK043351NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Understanding adaptive immunity against SARS-CoV-2 is a major requisite for the development of effective vaccines and treatments for COVID-19. CD4

Indexed as

COVID-19SARS-CoV-2AnimalsCD4-Positive T-LymphocytesEpitopes, T-LymphocyteHistocompatibility Antigens Class IIMiceNucleocapsidPeptidesSpike Glycoprotein, CoronavirusEpitopes, T-LymphocyteHistocompatibility Antigens Class IIPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2C57BL/6epitope mappingHexaProimmunodominancevFLIP

Identifiers

PMID38529279
PMCPMC10961420
OpenAlexW4392653106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.